Evaluation of the efficacy of a posaconazole and anidulafungin combination in a murine model of pulmonary aspergillosis due to infection with Aspergillus fumigatus

Posaconazole (PSC) in combination with anidulafungin (AFG) was evaluated in a murine model of pulmonary aspergillosis. Immunosuppressed animals were infected via the nasal cavity with two different A. fumigatus strains. The animals received PSC (oral, 20mg/kg/day) and/or AFG (i.p., 10mg/kg/day) for 7days. On day 8, the mice were euthanized and fungal burdens were determined from the lungs. Survival curves were constructed for mortality analysis. Compared to untreated groups, groups singly treated with PSC or AFG showed a reduced fungal burden in the lungs (P=0.0001 –0.006) and prevention of mortality (66.66% to 83.33% of survival).

Source: Diagnostic Microbiology and Infectious Disease - October 13, 2017 Category: Microbiology Authors: Laura Bedin Denardi, Francielli Pantella Kunz de Jesus, J éssica Tairine Keller, Carla Weiblen, Maria Isabel de Azevedo, Vanessa Oliveira, Janio Morais Santurio, Sydney Hartz Alves Source Type: research